Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
EBIT MarginEBITDA MarginEBT MarginFCF MarginInterest Coverage RatioNet MarginOperating MarginReturn on SalesTimes Interest Earned

KalVista Pharmaceuticals (KALV) EBITDA Margin (2016 - 2020)

KalVista Pharmaceuticals' EBITDA Margin history spans 7 years, with the latest figure at 185.25% for Q2 2020.

  • For Q2 2020, EBITDA Margin rose 10016.0% year-over-year to 185.25%; the TTM value through Jan 2021 reached 1073.61%, down 81633.0%, while the annual FY2025 figure was 3200.86%, 345501.0% up from the prior year.
  • EBITDA Margin for Q2 2020 was 185.25% at KalVista Pharmaceuticals, up from 583.96% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 90.77% in Q3 2016 and bottomed at 11059.65% in Q2 2017.
  • The 5-year median for EBITDA Margin is 202.44% (2019), against an average of 1395.81%.
  • The largest annual shift saw EBITDA Margin tumbled -510327bps in 2017 before it soared 1102597bps in 2018.
  • A 5-year view of EBITDA Margin shows it stood at 1000.0% in 2016, then soared by 55bps to 446.32% in 2017, then soared by 88bps to 55.63% in 2018, then tumbled by -147bps to 137.24% in 2019, then plummeted by -35bps to 185.25% in 2020.
  • Per Business Quant, the three most recent readings for KALV's EBITDA Margin are 185.25% (Q2 2020), 583.96% (Q1 2020), and 137.24% (Q4 2019).